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Lipopolysaccharide (LPS) activates innate immune responses
through TLR4MD-2. LPS binds to the MD-2 hydrophobic
pocket and bridges the dimerization of two TLR4MD-2 com-
plexes to activate intracellular signaling. However, exactly how
lipid A, the endotoxic moiety of LPS, activates myeloid lineage
cells remains unknown. Lipid IVA, a tetra-acylated lipid A pre-
cursor, has been used widely as a model for lipid A activation.
For unknown reasons, lipid IVA activates proinflammatory
responses in rodent cells but inhibits the activity of LPS in
human cells. Using stable TLR4-expressing cell lines and puri-
fiedmonomericMD-2, as well asMD-2-deficient bonemarrow-
derived macrophages, we found that both mouse TLR4 and
mouse MD-2 are required for lipid IVA activation. Computa-
tional studies suggested that unique ionic interactions exist
between lipid IVA and TLR4 at the dimerization interface in the
mouse complex only. The negatively charged 4-phosphate on
lipid IVA interacts with two positively charged residues on the
opposing mouse, but not human, TLR4 (Lys367 and Arg434) at
the dimerization interface.When replaced with their negatively
charged human counterparts Glu369 and Gln436, mouse TLR4
was no longer responsive to lipid IVA. In contrast, human TLR4
gained lipid IVA responsiveness when ionic interactions were
enabled by charge reversal at the dimerization interface, defin-
ing thebasis of lipid IVA species specificity. Thus, using lipid IVA
as a selective lipidA agonist, we successfully decoupled and cou-
pled two sequential events required for intracellular signaling:
receptor engagement and dimerization, underscoring the func-
tional role of ionic interactions in receptor activation.
Innate immunity is the first line of defense against exogenous
pathogens. Activation of the innate immune system produces
inflammatory cytokines such as tumor necrosis factor  and
interleukin-1, both of which help prevent infection and
enhance the adaptive immune response (1). The effect of these
cytokines can become detrimental when they are produced in
abundance, resulting in sepsis syndrome. Indeed, Gram-nega-
tive septic shock still has high mortality (20%) and remains a
leading cause of death in noncoronary intensive care units in
the United States (2, 3).
During Gram-negative bacterial infection, lipopolysaccha-
ride (LPS),4 the major component of the bacterial outer mem-
brane, activates the innate immune response through the Toll-
like receptor 4 (TLR4) and MD-2 complex. The active
component of LPS is lipid A, a partially conserved glycolipid
that anchors LPS into the outer membrane of Gram-negative
bacteria. Stimulatory lipid As, such as Escherichia coli lipid A,
usually have 6–8 acyl chains covalently linked to the digluco-
samine bis-phosphorylated backbone. The phosphate groups at
the 1,4-position are essential for the agonist activity of lipid A,
because monophosphorylated lipid A is greatly reduced in its
proinflammatory activity (4). In addition, both the number and
the length of the acyl chains are essential for the full agonist
activity of lipid A (5–7). In fact, the production of a hypoacy-
lated lipid A and the resulting evasion of innate immunity may
be associated with virulence in pathogens such as Yersinia pes-
tis (8). E. coli hexa-acylated lipid A acts as a pan-agonist for all
mammalian cells that express a complete LPS receptor com-
plex. The precursor of E. coli lipid A, tetra-acylated lipid IVA
(9), is only an agonist for some species of mammals (10).
Although commonly referred to as the LPS receptor, TLR4
does not directly bind LPS or any other LPS analog with high
avidity. Instead, MD-2, a 25-kDa co-receptor that physically
associates with TLR4 directly binds the lipid A moiety of LPS
(or its analogs) through the central hydrophobic pocket (11–
13). This hydrophobic pocket can accommodate up to five acyl
chains. In contrast to commonly held notions that the MD-2
pocket would expand to accommodate additional acyl chains
from stimulatory lipidA, the resolution of a co-crystal structure
of humanTLR4 (hTLR4), humanMD-2 (hMD-2), and LPS (12)
revealed that the sixth acyl chain of LPS is excluded from the
hydrophobic pocket and present on MD-2 surface. Both
hMD-2 and hTLR4 undergo “induced fit” conformational
changes to allow dimerization to occur (12).
Although an LPS antagonist in human cells, lipid IVA is an
LPS mimetic when tested with mouse cells (14, 15). Several
studies have been dedicated to understanding the molecular
determinants of this species specificity. The results of these
studies, however, are contradictory. Our group (16), as well as
that of Beutler and co-workers (17), proposed that TLR4 is
responsible for the species specificity of lipid IVA. Yet, based on
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similar approaches,Miyake and co-workers (14) andMiller and
co-workers (18) reported that MD-2 is responsible for the spe-
cies-specific responses to lipid IVA. A full interpretation of
these studies was not possible because neither group could ever
characterize the activity of human TLR4 with mouse MD-2
(mMD-2), probably because the latter protein is so poorly
expressed in transfected cell lines. Using a slightly different sys-
tem, i.e. comparing human versus equine genes, Bryant and
co-workers (19) demonstrated that under defined conditions,
MD-2 and TLR4 were both required for the species-specific
activation of lipid IVA, partially reconciling the contradiction
between the two theories.
The present study addresses both the molecular determi-
nants and the underlying mechanism of the species-specific
activation of lipid IVA in an attempt to truly understand the
mystery of lipid IVA activity and to extend our knowledge on
themechanismof lipidA activation.We found that bothmouse
TLR4 (mTLR4) andmMD-2 are required to confer LPS agonist
activity to lipid IVA, both in HEK293 cell lines that stably
express hTLR4 or mTLR4 and in MD-2-deficient bone mar-
row-derived macrophages (BMDMs). We used computational
docking and modeling to generate a dimeric mTLR4mMD-
2lipid IVA model to understand the underlying mechanism.
We found that unique ionic interactions exist between lipid IVA
and TLR4 in the mouse complex only. When these ionic
interactions were disrupted by mutagenesis, lipid IVA
responsiveness was severely impaired. In contrast, hTLR4
gained lipid IVA responsiveness when ionic interactions
were enabled by charge reversal at the dimerization inter-
face, defining the basis for lipid IVA species specificity.
Because lipid A also lacks the core polysaccharide, ionic
interactions between the phosphates on the lipid A digluco-
samine backbone and the positively charged residues on
TLR4 at the dimerization interface are likely to play a key
role in receptor dimerization and activation. Thus, we pro-
vide direct evidence that ionic interactions between the lip-
ids and TLR4, especially at the dimerization interface, play
an essential role in triggering the dimerization and activa-
tion of the LPS receptor.
EXPERIMENTAL PROCEDURES
MD-2 Expression and Purification—The MD-2 constructs
expressing hMD-2 andmMD-2with aC-terminal proteinA tag
were gifts from Dr. Jie-Oh Lee (11). MD-2 proteins were
expressed and purified as described earlier (11) (supplemental
Fig. S1). The MD-2 concentrations were determined by UV
absorbance at 280 nm using the extinction coefficients 18,490
and 14,650 litersM1cm1 for hMD-2 and mMD-2, respec-
tively (20).
LuciferaseAssay—TheHEK293/mTLR4YFP cell linewas con-
structed as described earlier (21). The E. coli precursor, lipid
IVA, was synthesized as described (22). The synthetic com-
pound, Eritoran, was a gift from the Eisai Research Institute
(Andover, MA). LPS from E. coli strain O111:B4 (Sigma) was
repurified by a repeat phenol chloroform extraction (23).
HEK293/hTLR4YFP and HEK293/mTLR4YFP cells were plated
in 96-well dishes at a density of 10,000 cells/well. The next day,
the cells were transfected with a plasmid encoding for an
NF-B-luciferase gene and a control plasmid expressing
Renilla luciferase. After overnight transfection, the superna-
tantswere removed, and the cells werewashed twicewith phos-
phate-buffered saline and replenishedwith serum-freemedium
consisting ofDMEMonly. The cells were stimulatedwith 1) the
indicated concentrations of LPS or lipid IVA and 2) increasing
concentrations of purified monomeric MD-2. After overnight
stimulation, the supernatants were removed, and the luciferase
activity wasmeasured in cell lysates.Renilla luciferase was used
for normalization.
The single, double, and triple mutants that swap surface
charges between hTLR4 and mTLR4 at the dimerization inter-
face were created by site-directed mutagenesis per the manu-
facturer’s instructions (QuikChange). All of themutationswere
verified by DNA sequencing (Genewiz, Inc., South Plainfield,
NJ). The effects of these mutations on LPS and lipid IVA signal-
ing were tested in HEK293 cells by transient transfection.
HEK293 cells were plated in 96-well plates at a density of 20,000
cells/well. The next day, the cellswere transfectedwith 1) one of
the hTLR4YFP or mTLR4YFP mutants (1 ng/well), 2) an NF-B-
luciferase plasmid (24), and 3) the Renilla luciferase plasmid.
After overnight transfection, the supernatantwas removed, and
the cells were washed twice with phosphate-buffered saline and
replenished with complete DMEM without serum. The cells
were stimulated with the indicated concentrations of mMD-2
and LPSlipid IVA overnight prior to the determination of lucif-
erase activity.
Tumor Necrosis Factor  Production—Mice deficient in
MD-2 were a gift fromDr. KensukeMiyake (25). BMDMswere
differentiated in the presence of 20%L929 conditionedmedium
for 10 days. The cells were then plated in 96-well plates at a
concentration of 50,000/well in complete DMEM supple-
mented with 10% fetal bovine serum. After attachment, the
supernatants were removed, and the cells were washed four
times with phosphate-buffered saline and replenished with
serum-free DMEM. The cells were then stimulated with 1) a
fixed concentration of lipid IVA or LPS, 2) decreasing concen-
trations of purified, monomericMD-2, and 3) 1g of CD14/ml
(26). After overnight stimulation, the supernatants were saved,
and the tumor necrosis factor  levels were measured by
enzyme-linked immunosorbent assay.
Docking Procedure between Lipid IVA and Human or Mouse
MD-2—Docking studies were performed usingAutoDock 4.0.1
(27, 28) with an AutoDockTool (29). The coordinates of lipid
IVA were subtracted from the co-crystal structure of hMD-2
and lipid IVA (Protein Data Bank code 2E59) (13). To reduce
expectation bias, the crystal structure of hMD-2 alone (Protein
Data Bank code 2E56) (13) instead of from the hMD-2lipid IVA
co-crystal structure (Protein Data Bank code 2E59) (13) was
used for docking with lipid IVA. The coordinates of mMD-2
were subtracted from the co-crystal structure of mMD-2 and
mTLR4 (Protein Data Bank code 2Z64) (11). Both hMD-2 and
mMD-2 were treated as rigid, and lipid IVA was treated as flex-
ible with 30 torsions during docking. TheAutoGrid parameters
are illustrated in detail in supplemental Table S1. Twenty struc-
tures were generated using genetic algorithm searches. A
default protocol was applied, with an initial population of 150
randomly placed individuals, a maximum number of 2.5 106
Lipid IVA Species Specificity
8696 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 285•NUMBER 12•MARCH 19, 2010
energy evaluations, and a maximum number of 2.7 104 gen-
erations. A mutation rate of 0.02 and a cross-over rate of 0.8
were used.
Generation of a Dimeric mTLR4mMD-2Lipid IVA Complex—
The coordinates of the docked mMD-2lipid IVA complex
were combined with the coordinates of mTLR4 extracted
from the mTLR4/mMD-2 co-crystal structure (Protein
Data Bank code 2Z64) (11) to generate a monomeric
mTLR4mMD-2lipid IVA complex. Two copies of mTLR4
mMD-2lipid IVA complexes were then aligned to the
hTLR4hMD-2LPS co-crystal structure to generate a
dimeric mTLR4mMD-2lipid IVA complex. The detailed
alignment procedure is as follows: the mTLR4 sequences
from the first mTLR4mMD-2lipid IVA complex were
aligned to one hTLR4 sequences in the dimeric
hTLR4hMD-2LPS co-crystal structure, and the mTLR4
sequences from the second mTLR4mMD-2lipid IVA com-
plex were aligned to the other hTLR4 sequences in the co-
crystal structure. The sequences ofMD-2 and lipids were not
used for the alignment. A dimeric mTLR4mMD-2lipid IVA
complex was readily observed after the alignment.
RESULTS
The FullMouse Receptor Complex, Consisting ofMouse TLR4
and Mouse MD-2, Is Required for the Full Agonist Activity of
Lipid IVA—To clarify the contradictions among different stud-
ies concerning lipid IVA species specificity, we developed stable
cell line systems in which hTLR4 (21) or mTLR4 was stably
expressed on the cell surface, allowing us to study each compo-
nent separately and consistently. Monomeric soluble MD-2 of
both human and mouse origin were purified (supplemental
Fig. S1) and used as the source for MD-2.
We examined the inducible luciferase activity using an
NF-B reporter construct transiently transfected in HEK293
cells. Both HEK293/hTLR4YFP (Fig. 1a) and HEK293/
mTLR4YFP cells (Fig. 1b) responded to LPS stimulation in an
MD-2 dose-dependent manner, regardless of the species of
MD-2 included. A peak response was observed at the MD-2
concentration of 40 ng/ml (1.3 nM), which likely reflects the
optimal concentration of MD-2 to interact with TLR4 in
HEK293 cells to activate intracellular signaling. Note that we
have consistently observed that HEK293/hTLR4YFP cells
responded to LPS more vigorously with hMD-2 than with
mMD-2, whereas HEK293/mTLR4YFP cells responded to LPS
similarly with hMD-2 and mMD-2.
When lipid IVA was used as the stimulant, HEK293/
hTLR4YFP cells did not respond to lipid IVA in the presence of
either hMD-2 or mMD-2 at all of the tested concentrations
(Fig. 1a); under these conditions, lipid IVA functioned as an LPS
antagonist (supplemental Fig. S2). This is consistent with our
previously reported data that lipid IVA acts as an antagonist in
the presence of hTLR4 (16). In comparison, HEK293/
mTLR4YFP cells (Fig. 1b) responded to lipid IVA stimulation
(gray diamond and open square) in a (mMD-2) dose-dependent
manner that peaked at the mMD-2 concentration of 200 ng/ml
(6.7 nM). This suggests that when bothmMD-2 andmTLR4 are
present, lipid IVA functions as an LPS agonist.
The titration experiments with hMD-2 in HEK293/
mTLR4YFP cells (Fig. 1b) show that at low concentrations of
hMD-2 (1.6 ng/ml or 53 pM), lipid IVA did not activate
HEK293/mTLR4YFP cells. At higher concentrations of hMD-2
(40 ng/ml, or 1.3 nM), lipid IVA activatedHEK293/mTLR4YFP
cells3–4-fold, about half of the response in comparison with
FIGURE 1. BothmTLR4 andmMD-2 are required for the full agonist activ-
ity of lipid IVA. HEK293/hTLR4
YFP cells (a), HEK293/mTLR4YFP cells (b), and
MD-2-deficient BMDMs (c)were stimulatedwith LPSlipid IVA andMD-2under
serum-free conditions. 1 g/ml soluble CD14 (sCD14) was included for stim-
ulations in MD-2-deficient BMDMs. After overnight stimulation, luciferase
activity was measured in HEK293 cell lysates, and mouse tumor necrosis fac-
tor levelsweremeasured in the supernatant ofMD-2-deficient BMDMs. The
data are reported as the means  S.D. of three independent wells for each
data point. The luciferase activities in a and b were normalized using Renilla
luciferase. One representative data set from four replicates is shown in the
figure. ‚, 1 g/ml LPS; F, 0.1 g/ml LPS;, 1 g/ml lipid IVA;, 0.1 g/ml
lipid IVA. The MD-2 concentrations used in a and b, from left to right, were
5000, 1000, 200, 40, 8, 1.6, 0.32, and 0 ng/ml.
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LPS stimulation. This indicates that lipid IVA can function as a
partial agonist in HEK293/mTLR4YFP cells and that under the
right conditions, bothMD-2 and TLR4 seem to be qualitatively
dictating the biological responses.
BMDMs fromMD-2Knock-outMice Required the Presence of
Mouse MD-2 to Respond to Lipid IVA—HEK293/hTLRYFP and
HEK293/mTLRYFP cell lines provide a stable environment to
quantitatively assess the activity of MD-2. However, these lines
are immortalized and genetically engineered; furthermore, they
express levels of TLR4 that are higher than true immune cells
(supplemental Fig. S3). In addition, HEK293 cells are not pro-
fessional phagocytes and have a limited profile of inducible
proinflammatory cytokines. BMDMs from MD-2 knock-out
mice were therefore tested for their responsiveness to lipid IVA
in the presence of purified mMD-2 or hMD-2.
MD-2-null BMDMs responded to LPS stimulation in an
hMD-2 dose-dependent manner, which reached a plateau at
the hMD-2 concentration of 40 ng/ml (Fig. 1c). This concen-
tration likely reflects the amount ofMD-2 necessary to saturate
TLR4 on the cell surface and to activate intracellular signaling
under physiological conditions. Similarly, MD-2-null BMDMs
responded to lipid IVA stimulation in the presence of mMD-2
in a dose-dependent manner until the maximally assessed
mMD-2 concentration (Fig. 1c) but did not respond to lipid IVA
stimulation when hMD-2 was included regardless of the
hMD-2 concentration added (Fig. 1c). This indicates that with
hMD-2, lipid IVA does not function as an LPS agonist toward
the mouse cells. The partial activation seen in HEK293/
mTLR4YFP cells by lipid IVA at high concentrations of hMD-2
was not observed, which is perhaps a reflection of the physio-
logical levels of mouse TLR4 expression. Thus, both mMD-2
and mTLR4 are required for the species-specific activation of
lipid IVA under physiological conditions.
In summary, it appears that when mouse TLR4 was
expressed, the activity of lipid IVAdependedupon the species of
MD-2. That is, when mouse TLR4 was matched with mouse
MD-2, lipid IVA was an agonist; when mouse TLR4 was
matchedwith humanMD-2, lipid IVA had no activity (except of
at higher levels of mTLR4 in
HEK293 cells) and hence func-
tioned as an antagonist. Thus, in the
presence of mouse TLR4, the spe-
cies from which MD-2 was derived
determined the character of the
response. In contrast, when human
TLR4 was expressed, lipid IVA was
not an LPS agonist regardless of the
species of MD-2. Hence, both
TLR4 and MD-2 appear to be
responsible for the species-spe-
cific response to lipid IVA, with the
dominance of one over the other
depending on the specific combi-
nation and expression levels of
TLR4MD-2 examined.
Lipid IVA Packs Superficially into
the Hydrophobic Pocket of Mouse
MD-2, with the Diglucosamine
Backbone Tilted toward the Cys95–Cys105 Loop—Computa-
tional dockingwas performed between lipid IVA andmMD-2 to
understand the essential role of mMD-2 in the species-specific
activation of lipid IVA. Mouse TLR4 was omitted from initial
docking because only MD-2, but not TLR4, has been demon-
strated to bind LPS or its analogs directly (13). We used the
AutoDock docking software, because this approach produces
ligandreceptor complexes that closely resemble co-crystal
structures (30). In a quality control experiment (supplemental
Fig. S4), AutoDock reproduced an hMD-2lipid IVA complex
highly similar to the co-crystal structure (13), with a root mean
square deviation of 0.74 Å and an inhibitory constant (Ki) of
144.85 pM. This Ki is very close to the experimental Kd value
between MD-2 and LPS (31).
In the docked lipid IVAmMD-2 complex, lipid IVA packs
well into the hydrophobic pocket of mMD-2 (Fig. 2a). The acyl
chains of lipid IVA interact extensively with residues lining the
hydrophobic pocket, especially residues adjacent to the Phe126
loop that has been implicated essential for receptor dimeriza-
tion (12). The 1,4-phosphates of lipid IVA interact weakly with
charged residues (e.g. Arg90 and Glu122) at the pocket entrance
(Fig. 2a), thus restraining the diglucosamine backbone of lipid
IVA to the pocket entrance. In comparison, none of the 4
strand residues, which have been suggested to be essential for
the species-specific recognition of lipid IVA (19), are directly
involved in lipid IVA interaction (Fig. 2a).
Compared with the hMD-2lipid IVA co-crystal structure
(13), lipid IVA packs more superficially in the hydrophobic
pocket of mMD-2, with the diglucosamine backbone of lipid
IVA tilted toward the Cys95–Cys105 loop (Fig. 2b). Conse-
quently, in the docked mMD-2lipid IVA complex, the 1-PO3
and 4-PO3 of lipid IVA are shifted 6.6 and 8.3 Å closer, respec-
tively, to the Cys95–Cys105 loop that directly bindsmTLR4 (11).
In addition, the fourth acyl chain (L4) of lipid IVAmoves toward
the surface (Fig. 2b) and hence is more exposed to the solvent.
The binding kinetics generated by AutoDock between mMD-2
and lipid IVA was 2.12 kcal mol1 for the expected binding
FIGURE 2. Lipid IVA packs tilted and shallowly in the mouse MD-2 hydrophobic pocket in the docked
mMD-2lipid IVA complex. ThedockedmMD-2lipid IVA complex is shown in twoperpendicular views ina and
overlaid to the hMD-2lipid IVA co-crystal structure in b. MD-2 is shown in ribbon views in a and b, and lipid IVA
is shown in sphere view in a and stick view in b. The residues interacting with lipid IVA are colored red, and the
4 strand is colored blue in a. The fourth acyl chain of lipid IVA is labeled L4 in both a and b. Green, mMD-2;
yellow, lipid IVA in mMD-2; pink, hMD-2; cyan, lipid IVA in hMD-2. The graphics were created using PyMol
(DeLano Scientific).
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energy (Gbin) and 28.05 mM for the expected inhibitory con-
stant (Ki, 298 K).
The 4-PO3 of Lipid IVA Bound to TLR4MD-2 Is Adjacent to
a Positively Charged Patch on the Opposite mTLR4 at the
Dimerization Interface—The coordinates of the mMD-2lipid
IVA complex were then combined with the crystal structure of
mTLR4 to generate anmTLR4mMD-2lipid IVA complex. This
complex is very similar to the monomeric hTLR4hMD-2LPS
complex isolated from the co-crystal structure (see supplemen-
tal Fig. S5a for the comparison) (12). Except for the opposite
orientation of the lipids, the diglucosamine backbone and the
two phosphates on the lipids are in very similar positions in the
two complexes (supplemental Fig. S5b). Thus, the docked
mTLR4mMD-2lipid IVA complex is in a favorable conforma-
tion to interact with another copy of mTLR4mMD-2lipid IVA
complex (denoted as mTLR4/mMD-2/lipid IVA from this
point on, to differentiate from the original mTLR4mMD-
2lipid IVA complex) to form a dimer. Indeed, when the
sequences of mTLR4 from the predicted mTLR4mMD-2lipid
IVA dimer were superimposed onto the crystal structure of
hTLR4 that was defined in the published hTLR4hMD-2LPS
(see details under “Experimental Procedures”), a dimeric
mTLR4mMD-2lipid IVA complex was readily observed
(Fig. 3a).
Close proximity was observed between the 4-PO3 on lipid
IVA and the positively charged residues on mTLR4 composed
of Lys367 and Arg434 at the dimer-
ization interface (Fig. 3b). The dis-
tances between the phosphorous
atom on the 4-PO3 of lipid IVA and
the nitrogen atoms on Lys367 and
Arg434 (of mTLR4) were calcu-
lated at 7.2 and 12.4 Å, respectively.
These distances are likely to be
shortened in the actual, active, and
dimeric mTLR4mMD-2lipid IVA
complex, because lipid IVA recog-
nition likely triggers induced fit
conformational changes in both
mTLR4 and mMD-2 to allow
dimerization to occur. These con-
formational changes likely resem-
ble those observed in the hTLR4
hMD-2LPS co-crystal structure
(12), i.e. the extension of the TLR4
solenoid and the folding back of
the Phe126 loop of MD-2. When
present in solution, the 4-PO3 on
lipid IVA likely attracts and inter-
acts with the positive patch on
mTLR4 at the dimerization inter-
face to facilitate and enable dimer-
ization and to initiate downstream
signaling.
Surface Charge Differences on
TLR4 at the Dimerization Interface
Account for the Specific Role of TLR4
in the Species-specific Activation of
Lipid IVA—The electrostatic surface charges at the dimeriza-
tion interface were predicted to be different between mTLR4
and hTLR4 (Fig. 3c). Mouse TLR4 has positively charged Lys367
and Arg434 at the dimerization interface, whereas hTLR4 has
the negatively charged Glu369 and Gln436 at these positions. In
addition, the noncharged Ser386 in mTLR4 corresponds to a
positively charged Lys388 in hTLR4. A charge reversal in this
area would therefore alter electrostatic forces on the 4-PO3 on
lipid IVA, changing the ionic interactions with lipid IVA at the
dimerization interface. We hypothesized that the essential role
of TLR4 in the species-specific activation of lipid IVA arises
from different electrostatic surface charges at the dimerization
interface.
To examine this possibility, we employed site-directed
mutagenesis to engineer single, double, and triple mutants that
swap surface charges between mTLR4 and hTLR4. The effects
of these mutations were examined by measuring the inducible
NF-B luciferase activity after transient transfection and lipid
IVA stimulation. Mouse MD-2 (at a concentration of 200
ng/ml) was included in all testing conditions, because only
mouse MD-2 functions with both hTLR4 and mTLR4.
Compared with the wild type mTLR4 construct, the mTLR4
mutants retained most of their LPS responsiveness (supple-
mental Fig. S6a), indicating that thesemutations do not disturb
the major structural motif on mTLR4 essential for LPS signal-
ing. Lipid IVA responsiveness, however, was modified by these
FIGURE 3. Close proximity is observed between the 4-PO3 on lipid IVA and the positively charged resi-
dues on mTLR4 at the dimerization interface. A dimeric mTLR4mMD-2lipid IVA model is shown in a. A
zoomed in view of the dimerization interface is shown in b. Molecules from the first complex are labeled as
mTLR4 (white ribbon), mMD-2 (green ribbon), and lipid IVA (yellow spheres or sticks), and molecules from the
second complex are labeled as mTLR4 (light purple ribbon), mMD-2 (olive ribbon), and lipid IVA (cyan sticks).
The phosphate groups on lipid IVA are colored red. Lys
367 and Arg434 are shown as blue spheres in a and as blue
sticks inb. Theelectrostatic surface charges (c) ofmTLR4 (left panel) andhTLR4 (right panel)were calculatedwith
MolMol (37). Red is for negatively charged surface, blue is for positively charged surface, and white is for
noncharged surface. Residues that differ betweenmTLR4 andhTLR4 are labeled in c. Thedashed circles ina and
c indicate the dimerization interface.
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mutations. As the dimerization interface become less positively
charged, the lipid IVA responsiveness decreased (supplemental
Fig. S6b), with the most profound effect on the double mutant
K367E/R434Q (Fig. 4, a and b). Thus, ionic interactions
between the 4-PO3 of lipid IVA and the positive patch on
mTLR4 at the dimerization interface appeared to be required
for lipid IVA activation.
Conversely, all of the hTLR4 mutants retained their LPS
responsiveness (supplemental Fig. S7a). However, the engraft-
ment of the positively charged residues from the dimerization
interface of mouse TLR4 to its human counterpart had a dra-
matic effect on lipid IVA signaling (supplemental Fig. S7b).
Enhanced responses to lipid IVA were weakly detected in the
single mutants E369K and Q436R but were more profoundly
observed in the double mutant E369K/Q436R (Fig. 4, c and d)
and the triple mutant E369K/K388S/Q436R (supplemental Fig.
S7b). In other words, the gain of positive charge at the dimer-
ization interface alone on hTLR4 is sufficient to convert the
mMD-2hTLR4 complex from a lipid IVA nonresponder to a
lipid IVA responder. Thus, mMD-2-mediated ionic interac-
tions between the 4-PO3 on lipid IVA and the positive patch on
TLR4 (wild type mTLR4 the hTLR4 double mutant E369K/
Q436R) are essential for the LPS mimetic activity of lipid IVA.
DISCUSSION
Several studies have been dedicated to study the underlying
mechanism for the species-specific recognition of lipid IVA,
because it has long been clear that understanding this pharma-
cology would offer important insights for how the LPS receptor
functions. Surprisingly, these studies have achieved contradic-
tory results. Although we (16) and Beutler and co-workers (17)
suggested that TLR4 is responsible for the species-specific acti-
vation of lipid IVA, Miller and co-workers (18) andMiyake and
co-workers (14) indicated thatMD-2 is responsible for this spe-
cies specificity. In all of these experiments, the animal serum
that included variable amounts of bovineMD-2was included in
the assays, which added a confounding variable. In addition,
transient transfection was generally used to introduce TLR4
and MD-2 into cells, and therefore, adequate expressions of
TLR4 and MD-2 were often assumed. This was especially the
case for mouse MD-2, which in our hands was minimally
expressed after transfection in anymammalian cell line.Miyake
and co-workers (14) appear to have had similar problems. Their
report focusing on the species-specific response to lipid IVA
revealed that they were unable to observe any response, regard-
less of the ligand, when mouse MD-2 was transfected with
human TLR4 (14). One important advance here is that we were
able to provide recombinant protein as the source of MD-2 at
defined concentrations. Hence, an important combination of
TLR4MD-2 can now be tested (mouse MD-2 plus human
TLR4). We found that mTLR4 is a prerequisite but not the sole
determinant for the agonist activity of lipid IVA, which also
required the presence of mMD-2. The dual requirement of
mTLR4 and mMD-2 for the agonistic activity of lipid IVA was
also confirmed in MD-2-deficient BMDMs, a relevant system
in which levels of mTLR4 are physiologic.
We then used computational docking and modeling to gen-
erate a working model for lipid IVA activation. It appears that
both mMD-2 and mTLR4 are required for lipid IVA signaling,
because only the mMD-2mTLR4 complex provides an envi-
ronment for lipid IVA to efficiently interact withmTLR4 at the
dimerization interface. The essential role of mTLR4 arises
mainly from its unique surface charge at the dimerization inter-
face (Lys367 and Arg434) and, hence, its capability to interact
with the 4-PO3 of lipid IVA through ionic interactions.
In comparison, the essential role of mMD-2 arises from its
ability to bind lipid IVA so that the ligand sits shallowly in its
hydrophobic pocket in a tilted conformation. This provides the
proper scaffold for the 4phosphate of lipid IVA to interact with
a positively charged patch on mouse TLR4 at the dimerization
interface and trigger receptor activation. This unique scaffold-
ing role of mMD-2 in packaging the tetra-acylated lipid IVA
derives from differences in its hydrophobic pocket in compar-
ison with hMD-2. The hydrophobic pockets of hMD-2 and
mMD-2 differ in their fine volume, dimension, and adjacent
surface charges (supplemental Fig. S8). Although the hydro-
phobic pocket of hMD-2 looks like a true pocket, i.e. a deep
invagination with a sealed bottom, the hydrophobic pocket of
mMD-2 is more likely a funnel structure (supplemental Fig.
S8a). Its pocket is wider and shallower near the entrance but
deeper at the bottom, rendering the appearance of a “hole” at
the bottom. The surface charges near the pocket entrance are
also slightly different between the two species ofMD-2. Human
MD-2 has the strongly positively charged Lys122 on the 7
strand that flanks the pocket entrance and Lys125 on the Phe126
FIGURE 4. Ionic interactions between lipid IVA and TLR4 at the dimeriza-
tion interfaceareessential for lipid IVA responsiveness.HEK293cellswere
transiently transfectedwith: 1) one of the four constructs:mTLR4YFPwild type
construct (WT), themTLR4YFP K367E/R434Qmutant (K367E/R434Q), hTLR4YFP
wild type construct, and the hTLR4YFP E369K/Q436R mutant (E369K/Q436R);
2) NF-B luciferase plasmid; and 3) a Renilla luciferase plasmid for luciferase
assay. After overnight transfection, the cells were stimulated with indicated
concentrations of LPSlipid IVA and mMD-2 (200 ng/ml) under serum-free
conditions. Luciferase activity was measured in cell lysates the next day. The
data are reported as the means  S.D. of three independent wells for each
data point. The luciferase activities were normalized from Renilla luciferase
activity. One representative data set from four replicates is shown in the
figure.
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loop that mediates dimerization (12). In comparison, mMD-2
has a negatively charged Glu122 at the pocket entrance and the
highly hydrophobic Leu125 on the Phe126 loop. The charge
reversal from Lys122 to Glu122 likely introduces repulsive forces
toward the bis-phosphate diglucosamine backbone of lipid IVA,
whereas a gain of hydrophobicity from Lys125 to Leu125 in
mMD-2 likely facilitates interactionwith the acyl chains of lipid
IVA. Consequently, we predict that lipid IVA packsmore super-
ficially in the mMD-2 hydrophobic pocket than in the human
receptor, with the diglucosamine backbone tilted toward the
Cys95–Cys105 loop (which binds MD-2 to TLR4). Supporting
data for this prediction have been reported byMuroi and Tana-
moto (32), who demonstrated that whenGlu122 wasmutated to
Lys122 onmMD-2, lipid IVA no longer functioned as an agonist.
In a sense, it is the hydrophobic pocket of mMD-2 that deter-
mines the species-specific pharmacology of lipid IVA with
respect to mMD-2.
In the published hTLR4hMD-2LPS co-crystal structure
(12), extensive hydrophobic interactions were observed at the
dimerization interface, involving hydrophobic residues Phe126,
Ile124, Leu87,Met85, andVal82 on hMD-2, the sixth acyl chain of
LPS, and hydrophobic residues Phe440, Leu444, and Phe463 on
the opposing hTLR4. When Phe126 on hMD-2 was mutated to
alanine, receptor dimerization did not occur (11). Hence, the
authors proposed that hydrophobic interactions are the pri-
mary driving force for receptor dimerization and activation (11,
12). This hypothesis was supported by mutagenesis studies
from Jerala and co-workers (33), showing that when the hydro-
phobic residues at the dimerization interface on MD-2 and
TLR4 were mutated to Ala, receptor activation was not
observed. Therefore, hydrophobic interactions at the dimeriza-
tion interface appeared to be the driving force for receptor
dimerization. These mutagenesis data on MD-2 and TLR4,
however, should not be confused with “mutagenesis on LPS.”
These data only demonstrated that hydrophobic interactions
arising from hydrophobic residues on MD-2 and TLR4 are
essential for receptor dimerization. They did not suggest that
hydrophobic interactions derived from the sixth acyl chain of
LPS at the dimerization interface are essential for receptor acti-
vation. In fact, the Phe126 loop on hMD-2 has to “fold back” to
accommodate the extra acyl chain of LPS at the dimerization
interface to allow dimerization to occur (11, 12), strongly sug-
gesting a redundancy of hydrophobic interactions at the dimer-
ization interface in regard to receptor dimerization.
It should be noted that the present study does not contradict
these findings. Except residue 85 which is a Met in hMD-2, but
an Ile in mMD-2, all of the hydrophobic residues onMD-2 and
TLR4 at the dimerization interface are completely conserved
between the two species. Therefore, hydrophobic interactions
between mMD-2 and mTLR4 are preserved at the dimeriza-
tion interface, which can still function as the primary driving
force for receptor dimerization. These interactions by them-
selves, however, are not sufficient to provide enough forces for
receptor dimerization. Additional forces such as ionic interac-
tions, as described here, are required for the formation of an
active receptor complex. Although the sixth acyl chain of E. coli
lipidAmay enhance receptor activation, it should be noted that
penta-acylated lipid A is capable of activating TLR4MD-2with
the same potency as hexa-acylated lipid A (34). Thus, whereas
hydrophobic forces are clearly critical for TLR4MD-2 activa-
tion, they are not sufficient.
A noticeable difference between the hTLR4hMD-2LPS
crystal structure and our lipid IVA activationmodel is the oppo-
site orientation of the lipids in the MD-2 hydrophobic pockets.
This difference should not result in a significant functional dif-
ference, because lipid IVA can be considered as functionally
symmetric. Additionally, it is plausible that lipid A inserts into
MD-2 in both orientations and that only one orientation was
well resolved by crystallographic approaches. This might hap-
pen if a particular crystal was analyzed inwhich one orientation
predominated or even if there were a preponderance of one
orientation over the other. It is also possible that the current
configuration of LPS is favored in the co-crystal structure,
because the co-crystallized LPS has an asymmetric core
polysaccharide that interacts extensively with TLR4 (12).
Lipid IVA has partial activity in the equine TLR4MD-2
receptor (19). One explanation for this observation is that the
relative orientation between equineMD-2 and equineTLR4 are
different fromother species. In particular, repulsive forces from
the phosphate of lipid IVA combinedwith residue 122 onMD-2
may not be required to “lift” lipid IVA up in the horse receptor,
accounting for the partial activity. Similar to human MD-2,
equine MD-2 has a positively charged residue, Arg122, at the
hydrophobic pocket entrance. Therefore, repulsive forces can-
not be generated at the pocket entrance to lift MD-2 up. How-
ever, in a recent separate study, we identified that not only
residues near the hydrophobic pocket ofMD-2 are essential for
lipid IVA activation but also residues at the A patch (11, 12) of
MD-2 that physically associate with TLR4 are important for
lipid IVA activation. Specifically, we identified that Gly69 and
Tyr42 on mMD-2 are required for a full response to lipid IVA.5
Because Gly69 and Tyr42 reside at the opposite surface of the
dimerization interface, these residues likely indirectly affect
receptor dimerization through affecting the MD-2TLR4 bind-
ing angle. Because equine MD-2 has Ser42 instead of Tyr42, the
binding angle between equineMD-2 and equine TLR4 could be
slightly different from the human and mouse complexes.
Hence, lipid IVA functions as a partial agonist for the equine
receptor.
Despite of all its implications, the resolution of the complete
TLR4MD-2/LPS crystal structure did not identify the charge
interactions on TLR4 at the dimerization interface that appear
to be so important for lipid A activity. In other words, the crys-
tal structure of TLR4MD-2/LPS did not allow us to make con-
clusions concerning whether the physical proximity between
the charged groups of LPS and hTLR4 play a functional role in
LPS activation. As can be seen here, the use of lipid IVA as a
selective lipidA agonist allows us to address questions concern-
ing the meaning of the receptor structure that might otherwise
be difficult to test. Because both MD-2 and TLR4 are required
for lipid IVA signaling, we were able to dissect the roles of TLR4
and MD-2 on receptor activation to identify a key ionic inter-
action that might otherwise have been missed.
5 J. Meng, J. R. Drolet, B. Monks, and D. T. Golenbock, unpublished data.
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Indeed, a practical application of the results presented here
are opportunities for designing better adjuvants. New com-
pounds with alterations in charge and the way in which they
bind to MD-2 (via acylation patterns and/or chain length) are
likely to affect immunogenicity differentially, and the effects of
alterations in lipid A structure should be amenable to predic-
tion using an approach similar to that presented here. The view
that minor alterations in adjuvants can have major effects on
outcomes has been borne out by recent clinical trials for impor-
tant new vaccines, such as the circumsporozoite vaccine for
malaria (35, 36).
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